Fragile X Syndrome (FXS) Treatment Market is estimated to be US$ 335.15 billion by 2030 with a CAGR of 19.8% during the forecast period

Fragile X Syndrome is a hereditary illness caused by a CGG trinucleotide expansion in the fragile X mental retardation 1 gene locus Xq27.3, known as a complete mutation (more than 200 CGG repetitions). It causes a hyper-methylated area in the gene promoter, which silences the gene and reduces the expression of fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. It is thought to be the most prevalent genetic cause of mental retardation. At adolescence and beyond, people with FXS have intellectual handicap, autism, hyperactivity, a long face, large or prominent ears, and macroorchidism. Language delay, sensory hyper arousal, and anxiety are common in young children with FXS. Intellectual disability, behavioral and academic difficulties, and a variety of physical traits are all symptoms of FXS. Fragile X Syndrome Treatment Market accounted for US$ 55.89 billion in 2020 and is estimated to be US$ 335.15 billion by 2030 and is anticipated to register a CAGR of 19.8%.

The report " Fragile X Syndrome (FXS) Treatment Market, By Type (Diagnosis, Treatment), By Related Disorders (Fragile X Tremor-Ataxia Syndrome, FMR1-Related Primary Ovarian Insufficiency, Fragile XE Syndrome, Renpenning Syndrome, Others), By End Users (Hospitals, Specialty Clinics Others), By Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

• In 2021, The US Food and Drug Administration (FDA) has granted Healx Investigational New Drug (IND) permission for a Phase 2a clinical investigation of the chemical HLX-0201 for Fragile X syndrome. The clinical trial will look for at least one new and effective combination therapy for Fragile X syndrome, the world's most common hereditary cause of autism and learning disabilities, which affects one in every 4000 boys and one in every 8000 girls worldwide.
• In 2021, Nova Mentis Life Science Corp., a pioneer in the production of serotonergic psychedelic chemicals, has stated that it is expanding its pre-clinical programme to create a unique diagnostic and therapy method for fragile X syndrome (FXS), a unmet medical need.

Analyst View:

The prevalence of fragile X syndrome is increasing due to a lack of public understanding about genetic illnesses that cause DNA abnormalities. Fragile X syndrome is more common in those who smoke, drink alcohol during pregnancy, or have inherited diseases. The pipeline for the worldwide fragile X syndrome market is expected to grow fast over the forecast period, owing to pharmaceutical and biotechnology companies' increased focus on conducting research programs to find effective therapeutic medicines for the disease's treatment.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Fragile X Syndrome (FXS) Treatment Market, By Type (Diagnosis, Treatment), By Related Disorders (Fragile X Tremor-Ataxia Syndrome, FMR1-Related Primary Ovarian Insufficiency, Fragile XE Syndrome, Renpenning Syndrome, Others), By End Users (Hospitals, Specialty Clinics Others), By Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Market Insights from the report:

Fragile X Syndrome Market accounted for US$ 55.89 billion in 2020 and is estimated to be US$ 335.15 billion by 2030 and is anticipated to register a CAGR of 19.8%. The Fragile X Syndrome Market is segmented based on type, related disorder, end-users, distribution channel and region.

• By Type, the Fragile X Syndrome Market is segmented into Diagnosis, Treatment.
• By Related Disorder, the Fragile X Syndrome Market is segmented into Fragile X Tremor-Ataxia Syndrome, FMR1-Related Primary Ovarian Insufficiency, Fragile XE Syndrome, Renpenning Syndrome, Others.
• By End-Users, the Fragile X Syndrome Market is segmented into Hospitals, Specialty Clinics Others.
• By Distribution Channel, the Fragile X Syndrome Market is segmented into Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others.
• By region, the Fragile X Syndrome Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape:

The major players covered in the Fragile X Syndrome (FXS) treatment market are Ovid Therapeutics., BELLUS Health Inc., AMO PHARMA, Neuren Pharmaceuticals, Anavex Life Sciences Corp., Karus Therapeutics. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- [email protected]

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com